Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | MAPKAPK5 | Q8IW41 | 11/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28002299 | 0.83 | AGBL2 (0.38) | AGBL2MAPKAPK5MAPK14MAPK1ADORA2A | |
| SCHEMBL25124308 | 0.82 | LMNA (0.37) | AGBL2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL31539703 | 0.81 | AGBL2 (0.38) | AGBL2KLKB1ADORA2AGRM5 | |
| SCHEMBL22048116 | 0.81 | TET2 (0.30) | NAAA | |
| SCHEMBL22912583 | 0.81 | KLKB1 (0.41) | KLKB1MAPKAPK5MAPK14MAPK1NAAA | |
| SCHEMBL134813 | 0.77 | AGBL2 (0.43) | AGBL2MAPK1ADORA2A | |
| SCHEMBL29941432 | 0.77 | AGBL2 (0.43) | AGBL2MAPK1ADORA2A | |
| SCHEMBL10264384 | 0.77 | AGBL2 (0.43) | AGBL2MAPK1ADORA2A | |
| SCHEMBL12468456 | 0.77 | AGBL2 (0.38) | AGBL2MAPKAPK5MAPK14MAPK1ADORA2A | |
| SCHEMBL25121174 | 0.77 | GRM5 (0.41) | MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229063-A1 | TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023161172-A1 | SUBSTITUTED N-BENZOIC ACID URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2021013800-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013799-A1 | SUBSTITUTED N-PHENYL URACILS, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | AGBL2 1419/4885KLKB1 4881/4885MAPKAPK5 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.